ClinicalTrials.gg
CompletedNCT02699372Updated Nov 24, 2017

The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RO6889450 in Healthy Volunteers

A Phase 1 interventional study of Placebo and RO6889450 in Healthy Volunteer, sponsored by Hoffmann-La Roche. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-24.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
164
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This randomized, single center, adaptive single ascending dose (Part 1) and multiple ascending dose (Part 2) study is designed to assess the safety, tolerability, pharmacokinetic, and pharmacodynamics following an oral administration of RO6889450 versus placebo in healthy volunteers. The anticipated duration of this study is approximately 18 weeks.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Healthy Volunteers
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A (BMI) between 18 to 30 kilogram per square meter (kg/m\^2) inclusive
  • Body weight in the range of 50 to 100 kilogram (kg) and right-handed - Part 2 only
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use methods
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm
  • Fluent in the language of the Investigator and study staff (including raters)
  • Able to participate and comply with the study restrictions

Exclusion criteria

Exclusion Criteria:

Part 1 and Part 2:

  • Disorders of the central nervous system (CNS), psychiatric disorders, behavioral disturbances
  • Participants who, in the Investigator's judgment, pose a suicidal or homicidal risk
  • Any personal or familial history (first degree) of seizures, epilepsy or other convulsive condition
  • Positive family history of psychosis or mood disorders up to first degree relative
  • Angle closure glaucoma, history or current significant ophthalmologic or neurologic condition that would adversely affect the pupillometry assessment
  • Suspicion of regular consumption of drug of abuse and/or any history of alcohol addiction with positive urine drug screen and/or positive alcohol urine test, or regular smoker
  • Positive result on (HBV), (HCV), or antibody (HIV 1 and 2)
  • Any prescribed or OTC medications (including vitamins or herbal remedies) taken within 4 weeks prior to first dosing or within 5 times the elimination half-life of the medication prior to first dosing (whichever is longer)
  • Taking any nutrients known to modulate activity (e.g., grapefruit juice; Seville orange) within 2 weeks prior to administration of study drugs
  • abnormalities in laboratory test results (including hepatic and renal panels, complete blood count, chemistry panel and urinalysis)
  • Participation in an drug or device study within 90 days prior to screening
  • Dietary restrictions that would prohibit the consumption of standardized meals
  • Concomitant disease or condition that could interfere with, or treatment of which might interfere with, the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the participant in this study

Part 2:

  • for magnetic resonance imaging (MRI) scans or any brain/head abnormalities restricting MRI eligibility. Any sensorial impairment such as deafness and reduced visual acuity which cannot be corrected in the fMRI scanner
  • Use of any psychoactive medication, or medications known to have effects on CNS or blood flow taken within 4 weeks prior to first dosing or within 5 times the elimination half-life of the medication prior to first dosing (whichever is longer)
  • Fulfilment of any of the MRI contraindications on the standard radiography screening questionnaire
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
164 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Healthy volunteers will receive the placebo equivalent to RO6889450 as oral capsules.

    Drug: Placebo

  • Experimental
    RO6889450: Part 1 Single Ascending Dose (SAD)

    Participants will undergo a series of screening visits prior to treatment and 4 weeks follow-up. Healthy volunteers will be enrolled in up to 7 dose groups (5 milligram \[mg\] to 450 mg) and will receive single oral dose of RO6889450 in the morning of the Day 1.

    Drug: RO6889450

  • Experimental
    RO6889450: Part 2 Multiple Ascending Dose (MAD)

    The starting dose for Part 2 MAD will be determined by analysis of safety and pharmacokinetic data of Part 1 SAD. All participants will receive RO6889450 orally for 14 days.

    Drug: RO6889450

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Dose Limiting Toxicities After Single Ascending Dose (SAD) - Part 1

    Time frame: up to 22 days

  2. Area Under the Curve from Time Zero to end of dosing interval (AUCtau) After Multiple Oral Ascending Doses - Part 2

    Time frame: Part 2: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 hr postdose on Day 1; predose on Days 2, 3, 4, 5, 6, 7, 8, 10, 12, 13, predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 hr postdose on Day 14, Days 15, 16, 17, 19, 20, 21

  3. Percentage of Participants With Dose Limiting Toxicities After Multiple Oral Ascending Doses (MAD) - Part 2

    Time frame: up to 35 days

  4. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 to inf)] After Single Ascending Dose - Part 1

    Time frame: Part 1: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 hours (hr) postdose on Day 1; Day 2, 3, 4, 6, 7, 8

  5. RO6889450 Maximum Plasma Concentration (Cmax) After Single Oral Ascending Doses

    Time frame: Part 1: predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 hours postdose on Day 1, Days 2, 3, 4, 6, 7, 8

  6. RO6889450 Maximum Plasma Concentration (Cmax) After Multiple Oral Ascending Doses

    Time frame: Part 2: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 hours postdose on Day 1, predose on Days 2, 3, 4, 5, 6, 7, 8, 10, 12, 13, predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 hours postdose on Day 14, Days 15, 16, 17, 19, 20, 21

  7. RO6889450 Minimum Observed Plasma Trough Concentration (Cmin)

    Time frame: Part 2: predose on Days 2, 3, 4, 5, 6, 7, 8, 10, 12, 13, predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 hours postdose on Day 14, Days 15

Secondary outcomes

  1. Time to Reach Maximum Observed Plasma Concentration (Tmax) After Multiple Ascending Dose - Part 2

    Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 hr postdose, Days 2, 3, 4, 5, 6, 7, 8, 10, 12, 13, predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 hr postdose on Day 14, Days 15, 16, 17, 19, 20, 21

  2. Terminal Rate Constant After Multiple Ascending Dose - Part 2

    Time frame: Part 2: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 hr postdose on Day 1, predose on Days 2, 3, 4, 5, 6, 7, 8, 10, 12, 13, predose, 0.5,1,1.5, 2, 2.5, 3,4, 6, 8, 12, 16 hr postdose on Day 14, Days 15, 16, 17, 19, 20, 21

  3. Apparent Terminal Half-Life (t1/2) After Multiple Ascending Dose - Part 2

    Time frame: Part 2: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 hr postdose on Day 1, predose on Days 2, 3, 4, 5, 6, 7, 8, 10, 12, 13, predose, 0.5, 1, 1.5, 2, 2.5, 3,4, 6, 8, 12, 16 hr postdose on Day 14, Days 15, 16, 17, 19, 20, 21

  4. Apparent Oral Clearance (CL/F) After Multiple Ascending Dose - Part 2

    Time frame: Part 2: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 hr postdose on Day 1, predose on Days 2, 3, 4, 5, 6, 7, 8, 10, 12, 13, predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 hr postdose on Day 14, Days 15, 16, 17, 19, 20, 21

  5. Cumulative Amount Excreted Unchanged in Urine (Ae) After Multiple Ascending Dose - Part 2

    Time frame: Part 2: predose, 0 to 6, 6 to 12, 12 to 24 hours postdose on Day 1, 14, 24 to 48 and 48 to 72 hours after Day 14 dosing

  6. Renal Clearance (CLR) After Multiple Ascending Dose - Part 2

    Time frame: Part 2: predose, 0 to 6, 6 to 12, 12 to 24 hours postdose on Day 1, 14, 24 to 48 and 48 to 72 hours after Day 14 dosing

  7. Fasting Glucose Concentrations After Multiple Ascending Dose - Part 2

    Time frame: Part 2: Baseline, Days 7, 15, 17

  8. Plasma Concentration of Prolactin - Part 2

    Time frame: Part 2: Day 1, 14, 15

  9. Scotopic Pupil Diameter as Assessed by Pupillometer - Part 2

    Time frame: Part 2: Day 1, 2, 14, 15

  10. Time to Reach Maximum Observed Plasma Concentration (Tmax) After Single Ascending Dose - Part 1

    Time frame: Part 1: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 hours (hr) postdose on Day 1, Days 2, 3, 4, 6, 7, 8

  11. Last Measurable Concentration (Clast) After Single Ascending Dose - Part 1

    Time frame: Part 1: predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 hours postdose on Day 1, Days 2, 3, 4, 6, 7, 8

  12. Time to Last Measurable Concentration (Tlast) After Single Ascending Dose - Part 1

    Time frame: Part 1: predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 hours postdose on Day 1, Days 2, 3, 4, 6, 7, 8

  13. Terminal Rate Constant After Single Ascending Dose - Part 1

    Time frame: Part 1: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 hr postdose on Day 1, Days 2, 3, 4, 6, 7, 8

  14. Apparent Terminal Half-Life (t1/2) After Single Ascending Dose - Part 1

    Time frame: Part 1: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 hr postdose on Day 1, Days 2, 3, 4, 6, 7, 8

  15. Area Under the Plasma Concentration Versus Time Curve From Zero to 24 Hours Post-Dose (AUC0-24h) After Single Ascending Dose - Part 1

    Time frame: Part 1: predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 hours postdose on Day 1, Days 2, 3, 4, 6, 7, 8

  16. Area Under the Plasma Concentration Versus Time Curve up to the Last Measurable Concentration (AUC0-last) After Single Ascending Dose - Part 1

    Time frame: Part 1: predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 hours postdose on Day 1, Days 2, 3, 4, 6, 7, 8

  17. Apparent Oral Clearance (CL/F) After Single Ascending Dose - Part 1

    Time frame: Part 1: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 hr postdose on Day 1, Days 2, 3, 4, 6, 7, 8

  18. Cumulative Amount Excreted Unchanged in the Urine (Ae) After Single Ascending Dose - Part 1

    Time frame: Part 1: predose, 0 to 6, 6 to 12, 12 to 24 hours postdose on Day 1, 24 to 48, 48 to 72 hours after Day 1 dosing

  19. Renal Clearance (CLR) After Single Ascending Dose - Part 1

    Time frame: Part 1: predose, 0 to 6, 6 to 12, 12 to 24 hours postdose on Day 1, 24 to 48, 48 to 72 hours after Day 1 dosing

  20. Accumulation Ratio for AUCtau (RAUC), Calculated as Day 14 AUC0-tau/Day 1 AUC0-tau - Part 2

    Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24 hours (hr) postdose on Day 1; predose, 0.5,1,1.5, 2, 2.5, 3,4, 6, 8, 12, 16, 24 hr postdose on Day 14

  21. Accumulation Ratio for Cmax (RCmax), Calculated as Day 14 Cmax / Day 1 Cmax - Part 2

    Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 hours (hr) postdose on Day 1; predose, 0.5,1,1.5, 2, 2.5, 3,4, 6, 8, 12, 16, 24 hr postdose on Day 14

  22. Accumulation Ratio for Ctrough RCtrough, Calculated as Day 14 Ctrough / Day 1 Ctrough - Part 2

    Time frame: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 hours (hr) postdose on Day 1; predose, 0.5,1,1.5, 2, 2.5, 3,4, 6, 8, 12, 16, 24 hr postdose on Day 14

  23. Fasting Glucose Concentrations After Single - Part 1

    Time frame: Part 1: Baseline, Day 4

  24. Change From Baseline in Glucose Level at Day 14 - Part 2

    Time frame: Baseline, Day 14

  25. Change From Baseline in Insulin Level at Day 14 - Part 2

    Time frame: Baseline, Day 14

  26. Change From Baseline in C-peptide Level at Day 14 - Part 2

    Time frame: Baseline, Day 14

  27. Change From Baseline in Gastric Inhibitory Polypeptide (GIP) Level at Day 14 - Part 2

    Time frame: Baseline, Day 14

  28. Change From Baseline in Glucagon-like Peptide-1 (GLP-1) Level at Day 14 - Part 2

    Time frame: Baseline, Day 14

  29. Columbia Suicide-Severity Rating Scale (C-SSRS) Scores - Part 1

    Time frame: Part 1: Day 4

  30. Columbia Suicide-Severity Rating Scale (C-SSRS) Scores - Part 2

    Time frame: Part 2: Day 15

  31. Capillary Blood Glucose Levels - Part 1

    Time frame: Part 1: Baseline through Day 4

  32. Capillary Blood Glucose Levels - Part 2

    Time frame: Part 2: Baseline through Day 17

  33. Urine Concentration of Dopamine Metabolite - Part 2

    Time frame: Baseline, Day 12, Day 13

  34. Plasma Concentration of Prolactin - Part 1

    Time frame: Part 1: Day 1, Day 2

  35. Change From Baseline in Body Weight at Days 7 and 15 - Part 2

    Time frame: Baseline, Day 7, 15

  36. Addiction Research Center Inventory (ARCI-49) Questionnaire Score - Part 2

    Time frame: Baseline, Day 1, 7, 14

  37. Scotopic Pupil Diameter as Assessed by Pupillometer - Part 1

    Time frame: Part 1: Day 1, 2

  38. Change From Baseline in Regional Cerebral Blood Flow (CBF), as Assessed by Functional Magnetic Resonance Imaging (fMRI) at Days 7 or 8, 12 or 13

    Time frame: Baseline, Day 7 or 8, 12 or 13

  39. Facial Expression Recognition Task (FERT) Score, as Assessed by Emotional Test Battery (ETB) - Part 2

    Time frame: Baseline, Day 12 or 13

  40. Reward Learning Task Score, as Assessed by Effort-Based Paradigms - Part 2

    Time frame: Baseline, Day 12 or 13

07

Study locations

1 site
  • PRA Health Sciences Early Development Services
    Zuidlaren, 9471 GP, Netherlands
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2016 to primary completion in Apr 2017, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2016
First posted
Mar 4, 2016
StartActual
Mar 21, 2016
Primary completionActual
Apr 14, 2017
CompletionActual
Apr 14, 2017
Last update
Nov 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02699372
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 4, 2016
Start date
Mar 21, 2016
Primary completion
Apr 14, 2017
Completion
Apr 14, 2017
Last update
Nov 24, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ralmitaront

Start the discussion